Highly stressful events can lead to post-traumatic stress disorder (PTSD)-a significant public health concern which existing treatments (e.g., psychotherapy and traditional medications) have shown marginal efficacy for.Psychedelics-alternatively called hallucinogens-are psychoactive substances that cause perception, mood, and cognitive changes.Because they are known for their impact on neuron...
Introdução: Uma parcela substancial de pacientes com Transtorno de Estresse Pós-Traumático (TEPT), estimada entre 30% e 50%, não alcança remissão com as terapias padrão-ouro (ISRS e psicoterapia). Este cenário de refratariedade constitui um desafio clínico significativo. A terapia assistida por 3,4-metilenodioximetanfetamina (MDMA) emerge como uma intervenção com potencial disruptivo para esta...
DELOS Desarrollo Local SostenibleNovember 12, 2025Maria Eduarda Mesquita Gonsalves, Beatriz Moreira Brazil, Maurício Cupello Peixoto
O Transtorno de Estresse Pós-Traumático (TEPT) é uma condição mental que pode surgir após experiências traumáticas, afetando a qualidade de vida dos indivíduos. O tratamento convencional envolve psicoterapia e farmacoterapia, contudo, nem sempre apresenta resultados satisfatórios. Nesse cenário, a psicoterapia assistida por 3,4-metilenodioximetanfetamina (MDMA) tem emergido como alternativa...
Psychedelic-assisted interventions are emerging as potential treatments for substance use disorders, including alcohol use disorder (AUD). While recent randomized controlled trials suggest efficacy for certain psychedelics and related compounds in treating AUD, the impact of naturalistic psychedelic use on problematic alcohol consumption remains underexplored. This study examines associations...
Serotonergic psychedelics and 3,4-methylendioxtmethamphetamine (MDMA) are promising treatments for mental disorders with a continuously evolving evidence base. We searched Pubmed/Scopus/clinical trial registries up to 08july2025 for double-blind randomized controlled trials (RCTs) testing MDMA or serotonergic psychedelics in patients with mental disorders. Primary outcomes were change in...
Abstract Background MDMA-related deaths increased by over 50% year on year in the most recent official statistics for England and Wales, despite prevalence of use being at its lowest level on record. Identifying the content and strength of ecstasy tablets enables public health and harm reduction services to better monitor unregulated drug markets and disseminate information about substances of...
Posttraumatic stress disorder (PTSD) is a serious and chronic mental health condition with limited effective treatment options. 3,4-methylenedioxymethamphethamine (MDMA)-assisted psychotherapy (MDMA-AT) has shown promise in phase 2 and phase 3 clinical trials, with many research participants reporting significant reductions in PTSD symptoms. However, the Federal Drug Administration (FDA)...
Increasing harms associated with nitrous oxide use have raised concerns, but limited evidence exists to inform harm reduction. This study aimed to identify how nitrous oxide is sourced, the products/forms used, awareness of health risks, engagement in harm reduction and experience of neurological symptoms. Data were collected via annual interviews (2021-2023) with cross-sectional convenience...
El Trastorno de Estrés Postraumático (TEPT) constituye un desafío clínico significativo debido a las altas tasas de resistencia a la farmacoterapia convencional y el abandono de las terapias tradicionales. Ante este escenario, el actual "renacimiento psicodélico" propone el uso controlado de sustancias psicoactivas como herramientas para potenciar el procesamiento del trauma. El objetivo de...
The emergence of microdosing introduced a novel approach to consuming classic psychedelic substances, such as LSD (lysergic acid diethylamide) and psilocybin mushrooms, in ways previously unconventional. Whereas traditional illicit substance use often seeks euphoric experiences, microdosing deliberately avoids such effects in favor of perceived self-enhancing benefits. Increasingly common in...
Lysergic acid diethylamide (LSD) and 3,4-Methylenedioxymethamphetamine (MDMA) are widely used psychoactive drugs and their potential use in psychiatric medicine is currently generating interest. The mechanism by which these drugs may assist recovery in various disorders such as addiction and post-traumatic stress disorder (PTSD) is still not well understood. Most investigations of the effects...
The illicit drug 3,4-methylenedioxymethamphetamine (MDMA) has recently shown promising efficacy as an adjunct to psychotherapy for posttraumatic stress disorder (PTSD), although the underlying mechanisms are poorly defined. In this review, we contextualize the emergence of MDMA-assisted psychotherapy (MDMA-AT) within 20th century psychiatry and trace its journey from assisting with military...
Regular recreational use of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") has been consistently linked to verbal memory dysfunctions, whose neurobiological origins remain unclear. Although neurochemical, structural, and functional alterations resulting from repeated MDMA intake have been identified in user populations, only limited knowledge exists regarding potential interrelationships...
Background: Posttraumatic stress disorder (PTSD) affects approximately 5-7% of the population, with conventional treatments often proving inadequate for some patients. Recent studies suggest that methylenedioxymethamphetamine (MDMA) combined with psychotherapy may offer a novel therapeutic approach. This systematic review evaluates the efficacy and safety of MDMA-assisted psychotherapy for the...
MDMA, 3,4-methylenedioxymethamphetamine (“ecstasy,” “molly”), is a distinctive entactogen that reverses the serotonin (5-HT) transporter to increase synaptic 5-HT, while also engaging catecholaminergic and oxytocinergic pathways. In clinical trials, MDMA-assisted psychotherapy has yielded substantial improvements in treatment-resistant posttraumatic stress disorder (PTSD), although regulatory...
Substance Use Disorder (SUD) is a chronic, relapsing mental health condition characterized by compulsive substance use despite harmful consequences. According to the World Health Organization, in 2021, approximately 39.5 million individuals worldwide suffered from drug use disorders, contributing to an estimated 600,000 deaths annually. Moreover, current pharmacological treatment, such as...
A depressão é um transtorno de grande impacto clínico e social, frequentemente resistente ao tratamento convencional, o que motiva a busca por estratégias terapêuticas complementares. Psicodélicos como a psilocibina e o MDMA têm se destacado por induzir respostas rápidas e duradouras em sintomas depressivos. Esta revisão integrativa analisou 14 estudos publicados entre 2015 e 2024, selecionados...
MDMA-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) shows promise, but attitudes and beliefs about this treatment, especially in symptomatic veterans, remain poorly understood. We sought to explore relevant attitudes in veterans receiving healthcare from Veterans Affairs as a step toward designing relevant surveys or psychoeducation materials for future work. We employed a...
3,4-Methylenedioxmethamphetamine (MDMA) has been shown to enhance social cognition, partly through its effects on oxytocin, a neuropeptide involved in social cognition. Despite growing evidence linking MDMA to increased oxytocin levels, no study has systematically examined this relationship across different doses, times, and participant characteristics. This systematic review and meta-analysis...
Introduction: MDMA (3,4-methylenedioxymethamphetamine) toxicity can cause life-threatening complications, including hyperthermia, rhabdomyolysis, and acute kidney injury (AKI). While AKI from rhabdomyolysis is well known, C3 glomerulopathy (C3G) following MDMA use, to our knowledge, has not been reported. We present a case of oliguric AKI and biopsy-proven C3G after MDMA overdose. Case...